pyrazines has been researched along with Cancer of Pancreas in 58 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (5.17) | 18.2507 |
2000's | 24 (41.38) | 29.6817 |
2010's | 24 (41.38) | 24.3611 |
2020's | 7 (12.07) | 2.80 |
Authors | Studies |
---|---|
Abdelsalam, M; Hastreiter, S; Ibrahim, HS; Krauss, L; Schneider, G; Schutkowski, M; Sippl, W; Vecchio, A; Zessin, M | 1 |
Hamamoto, T; Hirohara, M; Masuda, Y; Morimoto, Y; Takada, K; Takagi, A; Takeuchi, O; Watanabe, K | 1 |
de Assuncao, TM; Dusetti, N; Iovanna, J; Lomberk, G; Mathison, A; Salmonson, A; Toro-Zapata, J; Urrutia, G; Urrutia, R | 1 |
Benson, AB; Davis, RE; Javle, M; Kumar-Sinha, C; Lopez, CD; Maitra, A; Mettu, NB; Munugalavadla, V; Neelapu, S; Overman, M; Parra, ER; Patel, P; Tao, L; Vats, P; Xiao, L | 1 |
Bai, M; Che, X; Jing, W; Li, C; Li, Z; Liu, Y; Qu, X; Song, N; Teng, Z | 1 |
Brekken, RA; Hosein, AN; Maitra, A | 1 |
Hamamoto, T; Hirohara, M; Masuda, Y; Morimoto, Y; Takada, K; Takeuchi, O; Watanabe, K | 1 |
Anthony, LB; Carreira, VS; Chu, Z; Dahche, HM; Jiang, M; Koch, SE; Komurov, K; LaSance, K; Mercer, CA; Orr-Asman, MA; Plas, DR; Qi, X; Rubinstein, J; Thomas, HE; Worley, M | 1 |
Batra, SK; Dhanasingh, I; Kanteti, R; Kaushik, G; Kindler, HL; Kulkarni, P; Mambetsariev, B; Mirzapoiazova, T; Nasser, MW; Ponnusamy, MP; Riehm, JJ; Salgia, R; Seshacharyulu, P; Wang, J | 1 |
Christensen, JG; Ishiguro-Oonuma, T; McDonald, DM; Schriver, BJ; Sennino, B | 1 |
Aston-Mourney, K; Goldstein, LC; Hull, RL; Meier, DT; Samarasekera, T; Subramanian, SL; Zraika, S | 1 |
Carew, JS; Coffey, M; Espitia, CM; Freeman, JW; Kelly, KR; Nawrocki, ST; Zhao, W | 1 |
Almeida, GM; Coelho, MA; Coelho, SC; Juzenas, P; Pereira, MC; Rocha, S; Sampaio, P; Silva, FS | 1 |
Cheng, B; Gong, L; Jing, Y; Tang, X; Wu, GJ; Xu, M; Yang, B; Zheng, P | 1 |
Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G | 1 |
Chen, ZR; Huang, M; Min, H; Xu, M; Zheng, K; Zhou, JD; Zou, XP | 1 |
Chien, W; Ding, LW; Garg, M; Gery, S; Kitajima, S; Koeffler, PH; Lee, KL; Leong, WZ; Lim, SL; Poellinger, L; Sun, H; Sun, QY; Takao, S; Tan, SZ; Tokatly, I; Torres-Fernandez, LA; Xiao, J | 1 |
Almeida, GM; Coelho, MA; Frasco, MF; Pereira, Mdo C; Santos-Silva, F | 1 |
François, RA; Hochwald, SN; Kaye, FJ; Maeng, K; Nawab, A; Zajac-Kaye, M | 1 |
Barda, D; Barnard, D; Beckmann, R; Burke, T; Diaz, HB; Donoho, G; Jones, B; King, C; Marshall, M | 1 |
Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
Märten, A; Mehrle, S; Schmidt, J; Serba, S; von Lilienfeld-Toal, M; Zeiss, N | 1 |
Chen, Q; Hunsucker, SA; Kuhn, DJ; Orlowski, M; Orlowski, RZ; Voorhees, PM | 1 |
Chim, CS; Hwang, YY; Pang, C; Shek, TW | 1 |
Jin, J; Liu, H; Tong, HY; Wei, JY; Yu, WJ; Zhang, FJ; Zhu, WF | 1 |
Granberg, D; Hassan, S; Larsson, DE; Oberg, K; Wickström, M | 1 |
Butler, PC; Elashoff, M; Elashoff, R; Gier, B; Matveyenko, AV | 1 |
Jeong, KS; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Woo, SM; Yang, KY; Yoon, WJ; Yoon, YB | 1 |
Eckhardt, SG; Kulikowski, GN; Morelli, MP; Pitts, TM; Serkova, NJ; Spratlin, JL; Tentler, JJ | 1 |
Gundert-Remy, U; Spranger, J; Stammschulte, T | 1 |
Niessen, M; Spinas, GA; Xu, L | 1 |
Hahn, EG; Kalden, JR; Meister, S; Ocker, M; Voll, R; Wissniowski, TT | 1 |
Cao, Q; Dudek, AZ; Wang, H | 1 |
Brunner, TB; Charlton, PA; Fokas, E; McKenna, WG; Muschel, RJ; Pollard, JR; Prevo, R; Reaper, PM | 1 |
Brunner, TB; Charlton, PA; Cornelissen, B; Fokas, E; Gillies McKenna, W; Hammond, EM; Muschel, RJ; Olcina, MM; Pollard, JR; Prevo, R; Reaper, PM; Vallis, KA | 1 |
Abbruzzese, JL; Chiao, PJ; Dong, QG; Evans, DB; Fujioka, S; McDonnell, TJ; Peng, B; Schmidt, C; Sclabas, GM; Tsao, MS; Wu, T | 1 |
Abbruzzese, JL; Baker, C; Chiao, PJ; Dong, QG; Evans, DB; Frederick, WA; Fujioka, S; Schmidt, C; Sclabas, GM | 1 |
Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S | 1 |
McConkey, DJ; Nawrocki, ST; Sweeney-Gotsch, B; Takamori, R | 1 |
Grever, M; Kindler, HL; Kleiber, B; Shah, MH; Webb, I; Wright, J; Young, D | 1 |
Callery, MP; Canete, JJ; Chandler, NM | 1 |
Alberts, SR; Block, M; Burch, P; Foster, N; Jatoi, A; Kugler, J; Morton, R; Nguyen, PL | 1 |
Bai, J; Callery, MP; Demirjian, A; Marasco, W; Sui, J; Vollmer, CM | 1 |
Bold, RJ; Fahy, BN; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M | 1 |
Abbruzzese, JL; Boise, LH; Carew, JS; Chiao, PJ; Dunner, K; Huang, P; McConkey, DJ; Nawrocki, ST | 1 |
Abbruzzese, JL; Carew, JS; Dunner, K; Highshaw, RA; Huang, P; McConkey, DJ; Nawrocki, ST; Pino, MS | 1 |
Huang, DC; Sinicrope, FA; Yeung, BH | 1 |
Abbruzzese, JL; Andtbacka, RH; Bornmann, WG; Carew, JS; Chiao, PJ; Dunner, K; Highshaw, RA; Huang, P; McConkey, DJ; Nawrocki, ST; Pal, A; Pino, MS; Xiong, H | 1 |
Hughes, M; Micallef-Eynaud, P | 1 |
Bai, J; Callery, MP; Demirjian, A; Marasco, W; Sui, J | 1 |
Abbruzzese, JL; Andtbacka, R; Arumugam, T; Khanbolooki, S; Kurzrock, R; Logsdon, CD; McConkey, DJ; Nawrocki, ST; Pino, MS | 1 |
Gao, SL; Shen, HW; Tang, ZY; Wu, YL | 1 |
Clapper, ML; Lang, D; Leahy, K; Miknyoczki, S; Ruggeri, BA; Wood, M | 1 |
Bolli, GB; Brunetti, P; Ciofetta, M; Di Vincenzo, A; Epifano, L; Fanelli, C; Lepore, M; Modarelli, F; Pampanelli, S | 1 |
Hirahara, N; Minari, Y; Nio, Y; Ohmori, H; Sasaki, S; Takamura, M; Tamura, K | 1 |
Bold, RJ; McConkey, DJ; Virudachalam, S | 1 |
1 review(s) available for pyrazines and Cancer of Pancreas
Article | Year |
---|---|
Pancreatic cancer stroma: an update on therapeutic targeting strategies.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Extracellular Fluid; Extracellular Matrix; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Molecular Targeted Therapy; Pancreatic Neoplasms; Permeability; Pressure; Protein Kinase Inhibitors; Pyrazines; rho-Associated Kinases; Sulfonamides; Tumor Microenvironment | 2020 |
4 trial(s) available for pyrazines and Cancer of Pancreas
Article | Year |
---|---|
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Pancreatic Ductal; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myeloid-Derived Suppressor Cells; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Progression-Free Survival; Proof of Concept Study; Pyrazines; Tumor Microenvironment | 2020 |
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines | 2012 |
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoid Tumor; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome | 2004 |
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome | 2005 |
53 other study(ies) available for pyrazines and Cancer of Pancreas
Article | Year |
---|---|
Development of Pyrazine-Anilinobenzamides as Histone Deacetylase HDAC1-3 Selective Inhibitors and Biological Testing Against Pancreas Cancer Cell Lines.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Pancreatic Neoplasms; Protein Isoforms; Pyrazines; Structure-Activity Relationship | 2023 |
Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Combinations; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Oxonic Acid; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Tegafur | 2020 |
Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzimidazoles; Carcinoma, Pancreatic Ductal; Checkpoint Kinase 1; DNA Replication; Drug Synergism; Enzyme Inhibitors; Female; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrazines; Pyrazoles; Random Allocation; Xenograft Model Antitumor Assays | 2020 |
PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; B7-H1 Antigen; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Knockdown Techniques; Humans; Hyaluronan Receptors; Pancreatic Neoplasms; Pyrazines; Sulfones; Tumor Suppressor Protein p53; Up-Regulation | 2020 |
Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2020 |
mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
Topics: Animals; Carcinoid Heart Disease; Cell Line, Tumor; Drug Resistance, Neoplasm; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; Pleural Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinolones; Sulfonamides; Sulfones | 2018 |
Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice.
Topics: Animals; Antibodies; Antineoplastic Agents; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Indoles; Lymphatic Metastasis; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Confocal; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Triazoles; Vascular Endothelial Growth Factor C | 2013 |
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Hemizygote; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Male; Metformin; Mice; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Pancreatitis; Plaque, Amyloid; Pyrazines; Random Allocation; Recombinant Proteins; Sitagliptin Phosphate; Time Factors; Triazoles | 2013 |
Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brefeldin A; Caspases, Initiator; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Endoplasmic Reticulum Stress; Epithelial Cells; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Orthoreovirus, Mammalian; Pancreas; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; Reoviridae; Tunicamycin; Virus Replication; Xenograft Model Antitumor Assays | 2013 |
Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Synergism; Epithelial Cells; Gold; Humans; Nanoparticles; Pancreatic Ducts; Pancreatic Neoplasms; Polyethylene Glycols; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2013 |
Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Ceramides; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinase 5; Morpholines; Pancreatic Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyrazines | 2014 |
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |
Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Cells, Cultured; Chloroquine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering | 2014 |
Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.
Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, SCID; Naphthalenes; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA Splicing; Sulfonamides; Thiophenes; Toyocamycin; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2014 |
Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.
Topics: Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endocytosis; Humans; Lactic Acid; Nanoparticles; Pancreatic Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proteasome Inhibitors; Pyrazines; Spectroscopy, Fourier Transform Infrared; Telomerase; Transferrin | 2015 |
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Focal Adhesion Kinase 1; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neuroendocrine Tumors; Organic Chemicals; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Colonic Neoplasms; Deoxycytidine; DNA Damage; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Xenograft Model Antitumor Assays | 2016 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazines; RGS Proteins; Vascular Endothelial Growth Factor A | 2008 |
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
Topics: Anti-Inflammatory Agents; Apoptosis; Binding, Competitive; Boronic Acids; Bortezomib; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 13; Dexamethasone; Dipeptides; Drug Resistance, Neoplasm; Drug Synergism; Endothelium, Vascular; Humans; Immunoblotting; Multiple Myeloma; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Umbilical Veins | 2009 |
Restoration of chemosensitivity by bortezomib: implications for refractory myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Multiple Myeloma; Pancreatic Neoplasms; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Treatment Outcome | 2009 |
Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Middle Aged; Pancreatic Neoplasms; Plasmacytoma; Pyrazines; Retreatment; Treatment Outcome; Vincristine | 2009 |
The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.
Topics: Apoptosis; Benzophenanthridines; Boronic Acids; Bortezomib; Brefeldin A; Carcinoid Tumor; Carcinoma, Bronchogenic; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Lung Neoplasms; Naphthoquinones; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrazines | 2010 |
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Topics: Adverse Drug Reaction Reporting Systems; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Odds Ratio; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; United States; United States Food and Drug Administration; Venoms | 2011 |
Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2011 |
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Liver Neoplasms; Magnetic Resonance Spectroscopy; Metabolomics; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sulfonamides | 2011 |
GLP-1-based therapies: the dilemma of uncertainty.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; Uncertainty; Venoms | 2011 |
Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Thyroid Neoplasms; Triazoles; Venoms | 2011 |
Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.
Topics: Exenatide; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Pancreatic Ductal; Caspase 12; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Endoplasmic Reticulum; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mitochondria; Mucins; NF-kappa B; Pancreatic Neoplasms; Polymerase Chain Reaction; Protease Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Interference; Time Factors; Transcription Factor CHOP; Transcription Factors; Transfection; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Hypoxia; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Pyrazines; Radiation-Sensitizing Agents; Signal Transduction; Sulfones | 2012 |
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; DNA Damage; Female; Humans; Isoxazoles; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents | 2012 |
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Differentiation; Cell Division; Chloramphenicol O-Acetyltransferase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation; HeLa Cells; Humans; I-kappa B Proteins; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Promoter Regions, Genetic; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrophosphatases; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation | 2002 |
Function of nuclear factor kappaB in pancreatic cancer metastasis.
Topics: Animals; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Enzyme Inhibitors; Genes, Reporter; Humans; Immunohistochemistry; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; NF-kappa B; Pancreatic Neoplasms; Phenotype; Pyrazines; Retroviridae; Time Factors; Tumor Cells, Cultured | 2003 |
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle Proteins; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2003 |
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protease Inhibitors; Pyrazines; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; Immunoblotting; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Ribonucleotide Reductases; Tumor Cells, Cultured | 2004 |
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Gastrointestinal Agents; Humans; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Statistics, Nonparametric; Treatment Outcome; Weight Loss | 2005 |
Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Silencing; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Membrane Glycoproteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinones; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; Humans; Male; NF-kappa B; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2005 |
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calcium; Caspase Inhibitors; Caspases; Caspases, Initiator; Cycloheximide; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Molecular Chaperones; Oxidative Stress; Pancreas; Pancreatic Neoplasms; Phosphorylation; Protein Biosynthesis; Protein Processing, Post-Translational; Pyrazines; RNA, Small Interfering; Thapsigargin; Transcription Factor CHOP; Ubiquitin | 2005 |
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Calcium; Carcinogens; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cisplatin; Cytochromes c; Drug Interactions; Endoplasmic Reticulum; Enzyme Activation; Humans; Immunoblotting; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pyrazines; RNA, Small Interfering; Thapsigargin; Tumor Stem Cell Assay; Tunicamycin | 2005 |
PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 2; Cathepsin B; Cysteine Endopeptidases; Cytochromes c; Down-Regulation; Enzyme Inhibitors; Humans; Lysosomes; Membrane Proteins; Mitochondrial Membranes; Mitochondrial Proteins; Pancreatic Neoplasms; Permeability; Phosphatidylserines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; RNA, Messenger; Tumor Cells, Cultured | 2006 |
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Vorinostat; Xenograft Model Antitumor Assays | 2006 |
Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunohistochemistry; Liver Diseases; Male; Middle Aged; Multiple Myeloma; Pancreatic Neoplasms; Pyrazines; Tomography, X-Ray Computed | 2006 |
Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; NF-kappa B; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2006 |
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Pancreatic Neoplasms; Pyrazines; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2006 |
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53 | 2008 |
Chemopreventive activity of Oltipraz against N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters.
Topics: Animals; Anticarcinogenic Agents; Body Weight; Carcinogens; Carcinoma, Ductal, Breast; Cricetinae; Female; Glutathione Transferase; Immunohistochemistry; Liver; Mesocricetus; Nitrosamines; Pancreas; Pancreatic Neoplasms; Pyrazines; Thiones; Thiophenes; Tumor Suppressor Protein p53 | 1995 |
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans.
Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Brain; Cognition; Diabetes Mellitus, Type 1; Female; Glycerol; Homeostasis; Hormones; Humans; Hydroxybutyrates; Hypoglycemia; Hypolipidemic Agents; Insulin; Insulinoma; Ketone Bodies; Lactates; Lipolysis; Male; Pancreatic Neoplasms; Pyrazines; Reaction Time | 1993 |
A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cell Survival; Collagen; Drug Combinations; Extracellular Matrix; Humans; Laminin; Mice; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Proteoglycans; Pyrazines; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |